Panacea Biotec launches EasyFourPol in India
Receives registration of Valganciclovir powder for oral solution in Germany
Receives registration of Valganciclovir powder for oral solution in Germany
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The approval is for Cytomegalovirus, a type of Herpes virus
Subscribe To Our Newsletter & Stay Updated